PT1667693E - Composições e métodos para usar corpos lamelares com fins terapêuticos - Google Patents

Composições e métodos para usar corpos lamelares com fins terapêuticos Download PDF

Info

Publication number
PT1667693E
PT1667693E PT4768271T PT04768271T PT1667693E PT 1667693 E PT1667693 E PT 1667693E PT 4768271 T PT4768271 T PT 4768271T PT 04768271 T PT04768271 T PT 04768271T PT 1667693 E PT1667693 E PT 1667693E
Authority
PT
Portugal
Prior art keywords
compositions
methods
therapeutic purposes
lamellar bodies
lamellar
Prior art date
Application number
PT4768271T
Other languages
English (en)
Original Assignee
Lamellar Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamellar Biomedical Ltd filed Critical Lamellar Biomedical Ltd
Publication of PT1667693E publication Critical patent/PT1667693E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT4768271T 2003-09-25 2004-08-31 Composições e métodos para usar corpos lamelares com fins terapêuticos PT1667693E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322448.2A GB0322448D0 (en) 2003-09-25 2003-09-25 Using lamellar bodies to modify linear biological macro molecules
US10/827,172 US20050070877A1 (en) 2003-09-25 2004-04-19 Compositions and methods of using lamellar bodies for modifying linear biological macromolecules

Publications (1)

Publication Number Publication Date
PT1667693E true PT1667693E (pt) 2015-11-12

Family

ID=29286803

Family Applications (1)

Application Number Title Priority Date Filing Date
PT4768271T PT1667693E (pt) 2003-09-25 2004-08-31 Composições e métodos para usar corpos lamelares com fins terapêuticos

Country Status (9)

Country Link
US (4) US20050070877A1 (pt)
CY (1) CY1116815T1 (pt)
DK (1) DK1667693T3 (pt)
ES (1) ES2543979T3 (pt)
GB (1) GB0322448D0 (pt)
HU (1) HUE025129T2 (pt)
NZ (1) NZ546388A (pt)
PT (1) PT1667693E (pt)
SI (1) SI1667693T1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
GB0322448D0 (en) * 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US10471212B2 (en) * 2009-10-29 2019-11-12 W. L. Gore & Associates, Inc. Silicone free drug delivery devices
US9597458B2 (en) 2009-10-29 2017-03-21 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
US11612697B2 (en) 2010-10-29 2023-03-28 W. L. Gore & Associates, Inc. Non-fluoropolymer tie layer and fluoropolymer barrier layer
AU2015204395B2 (en) * 2011-05-27 2017-02-23 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
JP5701371B2 (ja) 2012-12-28 2015-04-15 花王株式会社 スフィンゴミエリン含有サプリメント
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
GB201511058D0 (en) * 2015-06-23 2015-08-05 Lamellar Biomedical Ltd Compositions and methods for using lamellar bodies for therapeutic purposes
JP2018533622A (ja) 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー． マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
EP3442519A4 (en) 2016-04-14 2019-12-04 Azura Opthalmics Ltd. SELENIUM DISULFIDE COMPOSITIONS FOR USE IN THE TREATMENT OF MEIBOMIUS GLAND DYSFUNCTION
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
FR2645878B1 (fr) 1989-04-17 1994-02-25 Institut Nal Sante Recherc Medic Sequences nucleotidiques d'actinomycetales, applications a la synthese ou a la detection d'acides nucleiques, produits d'expression de ces sequences et application en tant que compositions immunogenes
JPH02295933A (ja) 1989-05-10 1990-12-06 Wakamoto Pharmaceut Co Ltd 封入純度の高いプラスミノーゲン活性化因子封入リポソームの製造法
WO1991012026A1 (en) 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
ATE164230T1 (de) 1991-05-29 1998-04-15 Baxter Int 4verfahren und zusammensetzungen zur vorbeugung, diagnose und behandlung seröser entzündungen und damit verbundener störungen
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5462752A (en) 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
AUPM836794A0 (en) 1994-09-23 1994-10-20 University Of New England, The Improved method and composition for the treatment of ulcers
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2227065A1 (en) 1995-07-21 1997-02-06 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5736157A (en) 1995-10-11 1998-04-07 Williams; Kevin Jon Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions
AUPN766496A0 (en) 1996-01-22 1996-02-15 University Of New England, The Method and composition for the potentiation of anti-inflammatory drugs
DK1634949T3 (da) 1997-05-08 2011-03-28 Oncothyreon Inc Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
WO1998053800A1 (en) 1997-05-29 1998-12-03 Applied Biotechnologies, Inc. Compositions and methods for preventing adhesion
SE9702698D0 (sv) 1997-07-14 1997-07-14 Stig Bengmark Compositions for lubricating and separating tissues and biological membranes
ES2191355T3 (es) 1997-12-24 2003-09-01 Britannia Pharmaceuticals Ltd Uso de un tensioactivo para la preparacion de un medicamento para el tratamiento de trastornos del oido medio.
GB9807298D0 (en) 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
EP0976403A1 (en) 1998-07-30 2000-02-02 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Adjuvant comprising pulmonary surfactant
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2000069412A1 (en) 1999-05-14 2000-11-23 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
GB0007150D0 (en) 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0207653D0 (en) 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
CN1747738B (zh) 2002-10-29 2010-11-24 川塞夫有限公司 缓释抗感染剂
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules

Also Published As

Publication number Publication date
US20180153936A1 (en) 2018-06-07
DK1667693T3 (da) 2015-08-31
ES2543979T3 (es) 2015-08-26
US20090111773A1 (en) 2009-04-30
CY1116815T1 (el) 2017-03-15
HUE025129T2 (en) 2016-01-28
US20130280340A1 (en) 2013-10-24
NZ546388A (en) 2009-07-31
US9173901B2 (en) 2015-11-03
SI1667693T1 (sl) 2015-10-30
US9750766B2 (en) 2017-09-05
US20050070877A1 (en) 2005-03-31
GB0322448D0 (en) 2003-10-29

Similar Documents

Publication Publication Date Title
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1696910A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
IL174627A0 (en) Compositions and methods for treatment of burns
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
IL172647A0 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
PL378368A1 (pl) Kompozycje i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
IL219406A0 (en) Antiloading compositions and methods of selecting same
IL175427A0 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
EP1613266A4 (en) METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
EP1699431A4 (en) COMPOSITIONS FOR THE TREATMENT OF EARLIER DISEASES AND APPLICATION PROCEDURES
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2003299441A8 (en) Nf-hev compositions and methods of use
ZA200600025B (en) Methods and compositions for interferon therapy
EP1663255A4 (en) WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR
GB0303609D0 (en) Novel therapeutic method and compositions
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
SI1667693T1 (sl) Sestave in postopki za uporabo lamelastih teles v terapevtske namene
EP1625141A4 (en) GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF
GB0324523D0 (en) Compositions and methods of treatment
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0327050D0 (en) Therapeutic methods compositions and uses
PL1667693T3 (pl) Kompozycje i sposoby wykorzystywania ciał blaszkowatych do celów terapeutycznych
GB0303600D0 (en) Novel therapeutic method and compositions
EP1545539A4 (en) COMPOSITIONS FOR INDUCING INCREASED G (B) -CHIMIOKIN LEVELS AND METHODS OF USE THEREOF